Healthcare - Biotechnology - NASDAQ - US
$ 1.105
-13.7 %
$ 38.6 M
Market Cap
-0.35
P/E
CASH FLOW STATEMENT
-97 M
OPERATING CASH FLOW
104 M
INVESTING CASH FLOW
1.45 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
RAPT Therapeutics, Inc.
| Net Income | -117 M |
| Depreciation & Amortization | 1.22 M |
| Capital Expenditures | -1.12 M |
| Stock-Based Compensation | 17.1 M |
| Change in Working Capital | 5.5 M |
| Others | -5.89 M |
| Free Cash Flow | -98.2 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | |
|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||||
| Net Income | (116.8) | (83.8) | (69.2) | (52.9) | (43.0) | (36.1) | (29.1) |
| Depreciation & Amortization | 1.2 | 1.0 | 1.0 | 1.1 | 1.3 | 1.2 | 1.4 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 11 K | 17 K | 15 K |
| Stock Based Compensation | 17.1 | 11.3 | 10.0 | 8.7 | 2.1 | 1.2 | 0.7 |
| Other Operating Activities | (4.1) | 2.1 | 1.5 | 0.2 | 20 K | 14 K | 9 K |
| Change in Working Capital | 5.5 | (1.3) | (4.3) | 2.3 | 4.1 | 0.8 | (0.1) |
| Cash From Operations | (97.0) | (70.8) | (61.0) | (40.5) | (35.5) | (33.0) | (27.1) |
| INVESTING CASH FLOW | |||||||
| Capital Expenditures | (1.1) | (0.8) | (0.8) | (0.4) | (0.9) | (3.5) | (1.1) |
| Other Items | 105.3 | (44.6) | (80.6) | (87.0) | 45 K | 0 | 0 |
| Cash From Investing Activities | 104.1 | (45.5) | (81.3) | (87.4) | (0.8) | (3.5) | (1.1) |
| FINANCING CASH FLOW | |||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.4 | 1.4 | 2.0 | 1.9 | 14.4 | 105.2 | 60.0 |
| Cash From Financing Activities | 1.4 | 131.2 | 141.5 | 75.5 | 49.9 | 52.7 | 30.1 |
| CHANGE IN CASH | |||||||
| Net Change In Cash | 8.5 | 14.9 | (0.9) | (52.5) | 13.6 | 16.3 | 1.9 |
| FREE CASH FLOW | |||||||
| Free Cash Flow | (98.2) | (71.6) | (61.8) | (40.9) | (36.4) | (36.5) | (28.2) |